Perioperative targeted therapy has achieved significant improvement in early- and locally advanced-stage NSCLC patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.